NDA Partners LLC: A Development Partner to Biopharmaceutical Investors and Companies

Jack Reynolds, DVM

Practice Area Focus

  • Regulatory Strategy
  • Preclinical Development
  • Toxicology
  • Drug Safety


Dr. Reynolds joined NDA Partners as a Premier Expert consultant in 2014. He is an expert Toxicologist/Safety Scientist with experience in early stage biopharmaceutical companies, large pharma R&D, life sciences investments, and FDA advisory committees. Dr. Reynolds was co-founder and CEO of AnaBios Corp., a company that provides human-based drug response profiles in advance of clinical trials; Managing Partner at Pharma Capital Partners LP, a private equity firm focused on the development of new medicines; and Senior Vice President of R&D
at Pfizer Global Research. He was instrumental in creating a Center
for Molecular Safety Sciences at The Hamner Institutes for Health Sciences, and was the Interim Director of Safety Sciences and Translational Research.

In addition, Dr. Reynolds has been very active in industrial and professional activities in the areas of Safety Sciences, and has served
on the boards of the Health and Environmental Sciences Institute, Toxicology Education Foundation, and the Toxicology Forum. Highly regarded by his peers, he was named the initial Chair of the Non Clinical Studies Advisory Committee of the Food and Drug Administration (FDA). He founded the Drug Safety Executive Council and was the Chair of the Advisory Committee for nearly 3 years. He is currently an Adjunct Professor in the Division of Pharmacotherapy and Experimental Therapeutics, School of Pharmacy, The University of North Carolina.